XML 127 R70.htm IDEA: XBRL DOCUMENT v3.25.0.1
Debt, cash and cash equivalents and lease liabilities (Tables)
12 Months Ended
Dec. 31, 2024
Financial Instruments [Abstract]  
Summary of Changes in Financial Position Changes in Sanofi's financial position during the period were as follows:
(€ million)
2024
2023
2022
Long-term debt
11,791
14,347
14,857
Short-term debt and current portion of long-term debt
4,209
2,045
4,174
Interest rate and currency derivatives used to manage debt
137
139
187
Total debt
16,137
16,531
19,218
Cash and cash equivalents
(7,441)
(8,710)
(12,736)
Interest rate and currency derivatives used to manage cash and cash equivalents
76
(28)
(45)
Net debt(a)
8,772
7,793
6,437
(a)Net debt does not include lease liabilities, which amounted to €1,906 million as of December 31, 2024, €2,030 million as of December 31, 2023,
and 2,181 million as of December 31, 2022 (see the maturity analysis at Note D.17.2.).
Summary of Reconciliation of Carrying Amount to Value on Redemption Reconciliation of carrying amount to value on redemption
Value on redemption
(€ million)
Carrying
amount at
December 31,
2024
Amortized
cost
Adjustment
to debt
measured at
fair value
December 31,
2024
December 31,
2023
December 31,
2022
Long-term debt
11,791
30
119
11,940
14,546
15,143
Short-term debt and current portion
of long-term debt
4,209
4
5
4,218
2,045
4,178
Interest rate and currency derivatives
used to manage debt
137
(124)
13
(18)
(48)
Total debt
16,137
34
16,171
16,573
19,273
Cash and cash equivalents
(7,441)
(7,441)
(8,710)
(12,736)
Interest rate and currency derivatives
used to manage cash and cash
equivalents
76
76
(28)
(45)
Net debt
8,772
34
8,806
7,835
6,492
Disclosure of Movement In Total Debt The table below shows the movement in total debt during the period:
Cash flows from
financing activities
Non-cash items
(€ million)
December 31,
2023
Repayments
New
borrowings
Other
cash
flows(a)
Currency
translation
differences(b)
Reclassification
from non-current
to current
Other
items(c)
December 31,
2024
Long-term debt
14,347
(67)
63
(2,599)
47
11,791
Short-term debt and
current portion of
long-term debt
2,045
(605)
242
9
2,599
(81)
4,209
Interest rate and
currency derivatives
used to manage debt
139
(132)
146
(16)
137
Total debt
16,531
(672)
110
218
(50)
16,137
(a)These amounts mainly comprise €262 million related to the US commercial paper program.
(b)These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone.
(c)These amounts mainly comprise changes in accrued interest balances, and fair value adjustments.
The table below shows the movement in total debt during prior periods:
Cash flows from
financing activities
Non-cash items
(€ million)
December 31,
2022
Repayments
New
borrowings
Other
cash
flows(a)
Currency
translation
differences(b)
Reclassification
from non-current
to current
Other
items(c)
December 31,
2023
Long-term debt
14,857
(12)
48
(30)
(604)
88
14,347
Short-term debt and
current portion of
long-term debt
4,174
(3,672)
903
(21)
604
57
2,045
Interest rate and
currency derivatives
used to manage debt
187
(8)
29
(69)
139
Total debt
19,218
(3,684)
48
895
(22)
76
16,531
(a)These amounts mainly comprise €946 million related to the US commercial paper program.
(b)These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone.
(c)These amounts mainly comprise changes in accrued interest balances, and fair value adjustments.
Cash flows from
financing activities
Non-cash items
(€ million)
December 31,
2021
Repayments
New
borrowings
Other
cash
flows
Currency
translation
differences (a)
Reclassification
from non-current
to current
Other
items(b)
December 31,
2022
Long-term debt
17,123
(11)
1,549
56
(3,632)
(228)
14,857
Short-term debt and
current portion of
long-term debt
3,183
(2,707)
43
20
3,632
3
4,174
Interest rate and
currency derivatives
used to manage debt
(56)
(373)
366
7
243
187
Total debt
20,250
(2,718)
1,549
(330)
442
7
18
19,218
(a)These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone.
(b)These amounts include changes in accrued interest balances and fair value adjustments.
Summary of Debt by Type Valuation of Redemption
2024
2023
2022
(€ million)
Non-
current
Current
Total
Non-
current
Current
Total
Non-
current
Current
Total
Bond issues
11,876
2,716
14,592
14,416
718
15,134
15,044
3,817
18,861
Other bank borrowings
64
1,290
1,354
130
1,118
1,248
99
187
286
Other borrowings
3
3
6
6
6
6
Bank credit balances
209
209
203
203
168
168
Interest rate and currency
derivatives used to manage debt
13
13
(18)
(18)
(48)
(48)
Total debt
11,940
4,231
16,171
14,546
2,027
16,573
15,143
4,130
19,273
Cash and cash equivalents
(7,441)
(7,441)
(8,710)
(8,710)
(12,736)
(12,736)
Interest rate and currency
derivatives used to manage cash
and cash equivalents
76
76
(28)
(28)
(45)
(45)
Net debt(a)
11,940
(3,134)
8,806
14,546
(6,711)
7,835
15,143
(8,651)
6,492
(a)Net debt does not include lease liabilities (see the maturity schedule in Note D.17.2.)
Summary of Bond Issues Bond issues denominated in euros carried out by Sanofi are as follows:
Issuer
ISIN code
Issue date
Maturity
Annual
interest rate
Amount
(€ million)
Type
Sanofi
FR0013505104
March 2020
April 2025
1.000%
1,000
EMTN program
Sanofi
FR0014009KS6
April 2022
April 2025
0.875%
850
Standalone Prospectus
Sanofi
FR0012969038
September 2015
September 2025
1.500%
750
EMTN program
Sanofi
FR0013324340
March 2018
March 2026
1.000%
1,500
EMTN program
Sanofi
FR0012146801
September 2014
September 2026
1.750%
1,510
EMTN program
Sanofi
FR0013201639
September 2016
January 2027
0.500%
1,150
EMTN program
Sanofi
FR0013144003
April 2016
April 2028
1.125%
700
EMTN program
Sanofi
FR0013409844
March 2019
March 2029
0.875%
650
EMTN program
Sanofi
FR0014009KQ0
April 2022
April 2029
1.250%
650
Standalone Prospectus
Sanofi
FR0013324357
March 2018
March 2030
1.375%
2,000
EMTN program
Sanofi
FR0013505112
March 2020
April 2030
1.500%
1,000
EMTN program
Sanofi
FR0013409851
March 2019
March 2034
1.250%
500
EMTN program
Sanofi
FR0013324373
March 2018
March 2038
1.875%
1,250
EMTN program
Bond issues denominated in US dollars carried out by Sanofi under the public bond issue program (shelf registration statement)
registered with the US Securities and Exchange Commission (SEC) comprise:
Issuer
ISIN code
Issue date
Maturity
Annual
interest rate
Amount
($ million)
Type
Sanofi
US801060AD60
June 2018
June 2028
3.625%
1,000
SEC registered
Summary of Debt by Maturity at Value on Redemption
December 31, 2024
Current
Non-current
(€ million)
Total
2025
2026
2027
2028
2029
2030 and
later
Bond issues
14,592
2,716
3,010
1,150
1,666
1,300
4,750
Other bank borrowings
1,354
1,290
32
1
1
1
29
Other borrowings
3
3
Bank credit balances
209
209
Interest rate and currency derivatives used
to manage debt
13
13
Total debt
16,171
4,231
3,042
1,151
1,667
1,301
4,779
Cash and cash equivalents
(7,441)
(7,441)
Interest rate and currency derivatives used
to manage cash and cash equivalents
76
76
Net debt(a)
8,806
(3,134)
3,042
1,151
1,667
1,301
4,779
(a)Net debt does not include lease liabilities, which amounted to €1,906 million as of December 31, 2024; €2,030 million as of December 31, 2023;
and €2,181 million as of December 31, 2022 (see the maturity analysis at Note D.17.2.).
As of December 31, 2024, the main undrawn confirmed general-purpose credit facilities at holding company level amounted
to €8 billion, half of which expired in 2027 and the other half of which expires in 2030.
As of December 31, 2024, no single counterparty represented more than 6% of Sanofi’s undrawn confirmed credit facilities.
December 31, 2023
Current
Non-current
(€ million)
Total
2024
2025
2026
2027
2028
2029 and
later
Bond issues
15,134
718
2,600
3,010
1,150
1,606
6,050
Other bank borrowings
1,248
1,118
98
1
1
1
29
Other borrowings
6
6
Bank credit balances
203
203
Interest rate and currency derivatives used to manage
debt
(18)
(18)
Total debt
16,573
2,027
2,698
3,011
1,151
1,607
6,079
Cash and cash equivalents
(8,710)
(8,710)
Interest rate and currency derivatives used to manage
cash and cash equivalents
(28)
(28)
Net debt
7,835
(6,711)
2,698
3,011
1,151
1,607
6,079
December 31, 2022
Current
Non-current
(€ million)
Total
2023
2024
2025
2026
2027
2028 and
later
Bond issues
18,861
3,817
600
2,600
4,160
7,684
Other bank borrowings
286
187
61
38
Other borrowings
6
6
Bank credit balances
168
168
Interest rate and currency derivatives used to manage
debt
(48)
(48)
Total debt
19,273
4,130
661
2,600
4,160
7,722
Cash and cash equivalents
(12,736)
(12,736)
Interest rate and currency derivatives used to manage
cash and cash equivalents
(45)
(45)
Net debt
6,492
(8,651)
661
2,600
4,160
7,722
Summary of Debt by Interest Rate The table below splits net debt between fixed and floating rate, and by maturity, as of December 31, 2024. The figures shown are
values on redemption, before the effects of derivative instruments:
(€ million)
Total
2025
2026
2027
2028
2029
2030 and
later
Fixed-rate debt
14,592
2,716
3,010
1,150
1,666
1,300
4,750
of which euro
13,626
of which US dollar
966
% fixed-rate
90%
Floating-rate debt
1,566
1,502
32
1
1
1
29
of which euro
of which US dollar
1,221
% floating-rate
10%
Debt
16,158
4,218
3,042
1,151
1,667
1,301
4,779
Cash and cash equivalents
(7,441)
(7,441)
of which euro
(2,945)
of which US dollar
(4,204)
% floating-rate
100%
Net debt
8,717
(3,223)
3,042
1,151
1,667
1,301
4,779
To optimize the cost of debt or reduce the volatility of debt and manage its exposure to financial foreign exchange risk, Sanofi
uses derivative instruments (interest rate swaps, currency swaps, foreign exchange swaps and forward contracts) that alter the
fixed/floating rate split and the currency split of its net debt:
(€ million)
Total
2025
2026
2027
2028
2029
2030 and
later
Fixed-rate debt
11,098
(778)
3,010
1,150
1,666
1,300
4,750
of which euro
11,098
of which US dollar
% fixed-rate
69%
Floating-rate debt
5,074
5,010
32
1
1
1
29
of which euro
174
of which US dollar
3,507
% floating-rate
31%
Debt
16,171
4,231
3,042
1,151
1,667
1,301
4,779
Cash and cash equivalents
(7,365)
(7,365)
of which euro
(3,987)
of which US dollar
(1,005)
of which Singapore dollar
(822)
% floating-rate
100%
Net debt
8,806
(3,134)
3,042
1,151
1,667
1,301
4,779
Summary of Interest Rate of Net Debt at Value on Redemption The table below shows the fixed/floating rate split of net debt at value on redemption after taking account of derivative
instruments as of December 31, 2023 and December 31, 2022:
(€ million)
2023
%
2022
%
Fixed-rate debt
11,382
69%
16,386
85%
Floating-rate debt
5,191
31%
2,886
15%
Debt
16,573
100%
19,273
100%
Cash and cash equivalents
(8,738)
(12,781)
Net debt
7,835
6,492
Summary of Interest Rate Fluctuations of Debt Net of Cash and Cash Equivalents The projected full-year sensitivity of net debt to interest rate fluctuations for 2025 is as follows:
Change in short-term interest rates
Impact on pre-tax net
income
(€ million)
Impact on pre-tax
income/(expense) recognized
directly in equity
(€ million)
+100 bp
34
+25 bp
8
-25 bp
(8)
-100 bp
(34)
Summary of Debt by Currency Before and After Derivative Instrument The table below shows net debt by currency at December 31, 2024, before and after derivative instruments contracted to
convert the foreign-currency net debt of exposed entities into their functional currency:
(€ million)
Before derivative instruments
After derivative instruments
Euro
10,681
7,285
US dollar
(2,017)
2,502
Singapore dollar
(3)
(822)
Hungarian forint
(641)
Chinese yuan renminbi
(10)
226
Other currencies
65
256
Net debt
8,717
8,806
Summary of Debt by Currency After Derivative Instruments The table below shows net debt by currency at December 31, 2023 and 2022, after derivative instruments contracted to convert
the foreign currency net debt of exposed entities into their functional currency:
(€ million)
2023
2022
Euro
6,852
10,489
US dollar
1,169
(2,404)
Other currencies
(186)
(1,593)
Net debt
7,835
6,492
Summary of Market Value of Net Debt The market value of Sanofi’s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows:
(€ million)
2024
2023
2022
Market value
8,165
7,086
5,227
Value on redemption
8,806
7,835
6,492
Amount of Future Undiscounted Contractual Cash Flows Relating to Debt and Derivative Instruments Designated as Hedges of Debt The table below shows the amount of future undiscounted contractual cash flows (principal and interest) relating to debt and to
derivative instruments designated as hedges of debt:
December 31, 2024
Payments due by period
(€ million)
Total
2025
2026
2027
2028
2029
2030 and
later
Debt
17,077
4,328
3,226
1,288
1,780
1,388
5,067
Principal
16,049
4,105
3,047
1,151
1,667
1,300
4,779
Interest(a)
1,028
223
179
137
113
88
288
Net cash flows related to derivative instruments
161
71
34
34
21
1
Total
17,238
4,399
3,260
1,322
1,801
1,389
5,067
(a)Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2024.
The tables below show the amount of future undiscounted contractual cash flows (principal and interest) relating to debt and to
derivative instruments designated as hedges of debt as of December 31, 2023 and 2022:
December 31, 2023
Payments due by period
(€ million)
Total
2024
2025
2026
2026
2028
2029 and
later
Debt
17,710
2,153
2,912
3,187
1,285
1,719
6,454
Principal
16,468
1,917
2,703
3,011
1,151
1,607
6,079
Interest(a)
1,242
236
209
176
134
112
375
Net cash flows related to derivative instruments
143
47
32
23
24
16
1
Total
17,853
2,200
2,944
3,210
1,309
1,735
6,455
(a)Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2023.
December 31, 2022
Payments due by period
(€ million)
Total
2023
2024
2025
2026
2026
2028 and
later
Debt
20,408
4,206
868
2,803
3,184
1,283
8,064
Principal
18,932
3,928
661
2,601
3,011
1,151
7,580
Interest(a)
1,476
278
207
202
173
132
484
Net cash flows related to derivative instruments
209
24
60
38
31
31
25
Total
20,617
4,230
928
2,841
3,215
1,314
8,089
(a)Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2022.
Disclosure of Lease Liabilities A maturity analysis of lease liabilities as of December 31, 2024, 2023 and 2022 is set forth below:
Undiscounted future minimum lease payments
(€ million)
Total
Less than
1 year
From 1 to
3 years
From 3 to
5 years
More than
5 years
Discounting
effect
Total lease liabilities as of December 31, 2024(a)
1,906
377
498
386
819
(174)
Total lease liabilities as of December 31, 2023
2,030
291
448
360
989
(58)
Total lease liabilities as of December 31, 2022
2,181
320
515
436
1,129
(219)
(a)2024 amounts exclude Opella discontinued operations, while 2023 and 2022 include them.
Lease liabilities include leases relating to real estate assets located at Cambridge, MA (United States), which have a lease term of
15 years.